PubMed · 7162835
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
S Untario, R H Netty, B Permono. Hypertension after multiple transfusions.. https://pubmed.ncbi.nlm.nih.gov/7162835/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
A first-derivative spectrophotometric method for the determination of irbesartan (IRB) alone and in the presence of hydrochlorothiazide (HCT) is described. Measurements are made at the zero-crossing wavelength at 263.0 nm for IRB. The calibration graph was linear over the range 1.0-12.0 mg l(-1) of IRB, detection limit was 0.15 mg l(-1). HCT, in the presence of IRB was determined by direct spectrophotometric method at 317 nm. The calibration graph was linear over the range 2.0-50.0 mg l(-1) of HCT, detection limit was 0.25 mg l(-1). The proposed methods were successfully applied to the determinations of IRB and HCT in combined tablets.
OBJECTIVE: To compare the cost of ambulatory blood pressure monitoring (ABPM) with the putative savings made through treatment avoided by identification and non-treatment of those with "white coat" hypertension. DESIGN: A cost analysis based on a model of four alternative strategies (no ABPM, yearly, two-yearly, or three-yearly monitoring) over a seven-year period applied to a case series from Australian general practice. PARTICIPANTS: 62 patients newly diagnosed by their GPs as having hypertension and requiring drug treatment. MAIN OUTCOME MEASURES: The proportion of patients shown to not need treatment. The discounted costs to the Pharmaceutical Benefits Scheme, Medical Benefits Scheme and patients. RESULTS: 16 of 62 patients (26%; 95% CI, 15%-37%) were normotensive on ABPM and did not require treatment. All monitoring strategies are more expensive in the first year, but the initial costs are offset by year 3 and the monitoring strategies are cost saving thereafter. Sensitivity analysis shows that this result holds across a range of costs of pharmacotherapy and proportion of patients with white coat hypertension. CONCLUSION: The additional costs of 24-hour ABPM in the first year are offset by savings associated with patients with white coat hypertension who would otherwise have been treated.